Results · Apr-Jun 2026 · filed 5 Aug 2026
Biogen Pharmachem Industries Q1 FY27 results
Sales fell 71% to ₹0.44 crore from ₹1.5 crore in Apr-Jun 2025.
Operating profit fell 84% to ₹0.22 crore, an operating margin of 49.9% (down 37.2 points from a year ago).
Net profit fell 84% to ₹0.22 crore from ₹1.3 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −23%, net profit turns positive.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 0.4 | 1.5 | −71% |
| Operating profit (EBITDA) | 0.2 | 1.3 | −84% |
| Operating margin | 49.9% | 87.2% | −37.2 pts |
| Net profit | 0.2 | 1.3 | −84% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 5 Aug 2026Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
- 5 Aug 2026Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
- 5 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting Held On 5Th August 2026.
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.